Michael Westover
Neurology · Boston, MANPI 1184653487
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,250 of the $2,535 with a category attached, or 88.8%. Bristol Myers Squibb accounts for 88.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $2,280 and has fallen 97.3% since, to $61 in 2025.
Across 7 payments — averaging $362.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$2K
- UCB, Inc.$105
- Neurelis, Inc.$83
- Jazz Pharmaceuticals Inc.$61
- Livanova USA, Inc.$35
Across 5 payments — averaging $128,419 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$595K
- Ceribell, Inc.$47K
What the payments were for
- Consulting fees$2,25089%
- Food & beverage$28511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 1 | $2,250 |
| UCB, Inc. | 2 | $105 |
| Neurelis, Inc. | 1 | $83 |
| Jazz Pharmaceuticals Inc. | 2 | $61 |
| Livanova USA, Inc. | 1 | $35 |
How this compares
$2,535 in reported general payments places this provider in the 65th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BanzelRufinamide | 19 | $120,809 |
| EpidiolexCannabidiol (Cbd) | 11 | $38,609 |
| AptiomEslicarbazepine Acetate | 26 | $32,142 |
| Clobazam | 45 | $3,356 |
| Levetiracetam | 72 | $2,139 |
| Levetiracetam ErLevetiracetam | 18 | $1,441 |
| Zonisamide | 24 | $998 |
| Lamotrigine | 32 | $916 |
| Phenobarbital | 21 | $889 |
| Lacosamide | 23 | $873 |
| Divalproex Sodium | 19 | $545 |
| Topiramate | 20 | $411 |
| Clonazepam | 20 | $225 |
| Paroxetine Hcl | 13 | $82 |
| Lorazepam | 19 | $81 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.